{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:11:51Z","timestamp":1762297911493},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T00:00:00Z","timestamp":1350432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s12185-012-1189-4","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T22:24:20Z","timestamp":1350512660000},"page":"562-571","source":"Crossref","is-referenced-by-count":32,"title":["Current and future management of NK\/T-cell lymphoma based on clinical trials"],"prefix":"10.1007","volume":"96","author":[{"given":"Motoko","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,17]]},"reference":[{"key":"1189_CR1","volume-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001."},{"key":"1189_CR2","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008."},{"key":"1189_CR3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s lymphoma classification project. Ann Oncol. 1998;9:717\u201320.","journal-title":"Ann Oncol."},{"key":"1189_CR4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"1189_CR5","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/sj.leu.2403955","volume":"19","author":"YL Kwong","year":"2005","unstructured":"Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19:2186\u201394.","journal-title":"Leukemia"},{"key":"1189_CR6","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1365-2141.2007.06835.x","volume":"139","author":"K Oshimi","year":"2007","unstructured":"Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139:532\u201344.","journal-title":"Br J Haematol"},{"key":"1189_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.2009.07802.x","volume":"147","author":"R Liang","year":"2009","unstructured":"Liang R. Advances in the management and monitoring of extranodal NK\/T-cell lymphoma, nasal type. Br J Haematol. 2009;147:13\u201321.","journal-title":"Br J Haematol"},{"key":"1189_CR8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12185-010-0720-8","volume":"92","author":"SJ Kim","year":"2010","unstructured":"Kim SJ, Kim WS. Treatment of localized extranodal NK\/T cell lymphoma, nasal type. Int J Hematol. 2010;92:690\u20136.","journal-title":"Int J Hematol"},{"key":"1189_CR9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11912-012-0245-9","volume":"14","author":"R Suzuki","year":"2012","unstructured":"Suzuki R. NK\/T-cell lymphomas: pathobiology, prognosis and treatment paradigm. Curr Oncol Rep. 2012;14:395\u2013402.","journal-title":"Curr Oncol Rep."},{"key":"1189_CR10","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","volume":"27","author":"M Yamaguchi","year":"2009","unstructured":"Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594\u2013600.","journal-title":"J Clin Oncol"},{"key":"1189_CR11","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","volume":"27","author":"SJ Kim","year":"2009","unstructured":"Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27:6027\u201332.","journal-title":"J Clin Oncol"},{"key":"1189_CR12","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","volume":"99","author":"M Yamaguchi","year":"2008","unstructured":"Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia. Cancer Sci. 2008;99:1016\u201320.","journal-title":"Cancer Sci"},{"key":"1189_CR13","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834\u20139.","journal-title":"Blood"},{"key":"1189_CR14","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410\u20136.","journal-title":"J Clin Oncol"},{"key":"1189_CR15","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","volume":"113","author":"WY Au","year":"2009","unstructured":"Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113:3931\u20137.","journal-title":"Blood"},{"key":"1189_CR16","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdp418","volume":"21","author":"R Suzuki","year":"2010","unstructured":"Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21:1032\u201340.","journal-title":"Ann Oncol"},{"key":"1189_CR17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2000.18.1.54","volume":"18","author":"GE Kim","year":"2000","unstructured":"Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54\u201363.","journal-title":"J Clin Oncol"},{"key":"1189_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","volume":"24","author":"YX Li","year":"2006","unstructured":"Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. J Clin Oncol. 2006;24:181\u20139.","journal-title":"J Clin Oncol"},{"key":"1189_CR19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0360-3016(01)01800-4","volume":"51","author":"N Shikama","year":"2001","unstructured":"Shikama N, Ikeda H, Nakamura S, Oguchi M, Isobe K, Hirota S, et al. Localized aggressive non-Hodgkin\u2019s lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys. 2001;51:1228\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1189_CR20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0360-3016(02)02916-4","volume":"54","author":"MM Cheung","year":"2002","unstructured":"Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK\/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54:182\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1189_CR21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ijrobp.2003.12.006","volume":"59","author":"WS Koom","year":"2004","unstructured":"Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, et al. Angiocentric T-cell and NK\/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59:1127\u201337.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1189_CR22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/cncr.21656","volume":"106","author":"K Isobe","year":"2006","unstructured":"Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, et al. Extranodal natural killer\/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106:609\u201315.","journal-title":"Cancer"},{"key":"1189_CR23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2008.04.058","volume":"73","author":"JE Bekelman","year":"2009","unstructured":"Bekelman JE, Yahalom J. Quality of radiotherapy reporting in randomized controlled trials of Hodgkin\u2019s lymphoma and non-Hodgkin\u2019s lymphoma: a systematic review. Int J Radiat Oncol Biol Phys. 2009;73:492\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1189_CR24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.ijrobp.2007.12.002","volume":"71","author":"HT Eich","year":"2008","unstructured":"Eich HT, Engenhart-Cabillic R, Hansemann K, Lukas P, Schneeweiss A, Seegenschmiedt H, et al. Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin\u2019s lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys. 2008;71:1419\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1189_CR25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10147-011-0264-9","volume":"17","author":"N Sanuki","year":"2012","unstructured":"Sanuki N, Ishikura S, Shinoda M, Ito Y, Hayakawa K, Ando N. Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303. Int J Clin Oncol. 2012;17:105\u201311.","journal-title":"Int J Clin Oncol."},{"key":"1189_CR26","doi-asserted-by":"crossref","unstructured":"Oguchi M, Kagami Y, Ishikura S, Nihei K, Ito Y, Yamaguchi M, et al. Upfront radiotherapy with concurrent chemotherapy for localized nasal NK\/T-cell lymphoma: radiotherapy quality assurance (QA) review in Japan Clinical Oncology Group (JCOG) Trial 0211. Int J Radiat Oncol Biol Phys. 2008 (abstr 2682);72:S474.","DOI":"10.1016\/j.ijrobp.2008.06.1402"},{"key":"1189_CR27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","volume":"24","author":"J Lee","year":"2006","unstructured":"Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612\u20138.","journal-title":"J Clin Oncol"},{"key":"1189_CR28","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/annonc\/mdn147","volume":"19","author":"TM Kim","year":"2008","unstructured":"Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, et al. Clinical heterogeneity of extranodal NK\/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008;19:1477\u201384.","journal-title":"Ann Oncol"},{"key":"1189_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998;339:21\u20136.","journal-title":"N Engl J Med"},{"key":"1189_CR30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","volume":"12","author":"WS Kim","year":"2001","unstructured":"Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma? Ann Oncol. 2001;12:349\u201352.","journal-title":"Ann Oncol"},{"key":"1189_CR31","first-page":"427","volume":"91","author":"SH Lee","year":"2006","unstructured":"Lee SH, Ahn YC, Kim WS, Ko YH, Kim K, Park K. The effect of pre-irradiation dose intense CHOP on anthracycline resistance in localized nasal NK\/T-cell lymphoma. Haematologica. 2006;91:427\u20138.","journal-title":"Haematologica"},{"key":"1189_CR32","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","volume":"76","author":"M Yamaguchi","year":"1995","unstructured":"Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351\u20136.","journal-title":"Cancer"},{"key":"1189_CR33","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.V89.8.2966","volume":"89","author":"B Drenou","year":"1997","unstructured":"Drenou B, Lamy T, Amiot L, Fardel O, Caulet-Maugendre S, Sasportes M, et al. CD3\u2212 CD56+ non-Hodgkin\u2019s lymphomas with an aggressive behavior related to multidrug resistance. Blood. 1997;89:2966\u201374.","journal-title":"Blood"},{"key":"1189_CR34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.V93.2.599","volume":"93","author":"M Egashira","year":"1999","unstructured":"Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93:599\u2013606.","journal-title":"Blood"},{"key":"1189_CR35","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2001.19.10.2665","volume":"19","author":"S Imashuku","year":"2001","unstructured":"Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, et al. Requirement for etoposide in the treatment of Epstein\u2013Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19:2665\u201373.","journal-title":"J Clin Oncol"},{"key":"1189_CR36","first-page":"635","volume":"35","author":"M Okamoto","year":"1994","unstructured":"Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, et al. Salvage chemotherapy for relapsed\/refractory aggressive non-Hodgkin\u2019s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki. 1994;35:635\u201341.","journal-title":"Rinsho Ketsueki."},{"key":"1189_CR37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3960\/jslrt.41.93","volume":"41","author":"M Yamaguchi","year":"2001","unstructured":"Yamaguchi M, Ogawa S, Nomoto Y, Oka K, Taniguchi M, Nakase K, et al. Treatment outcome of nasal NK-cell lymphoma: a report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematop. 2001;41:93\u20139.","journal-title":"J Clin Exp Hematop"},{"key":"1189_CR38","doi-asserted-by":"crossref","unstructured":"Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: an updated analysis of the Japan Clinical Oncology Group study JCOG0211. J Clin Oncol. 2012. doi: 10.1200\/JCO.2012.45.6541 .","DOI":"10.1200\/JCO.2012.45.6541"},{"key":"1189_CR39","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdh143","volume":"15","author":"JY You","year":"2004","unstructured":"You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)\/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15:618\u201325.","journal-title":"Ann Oncol"},{"key":"1189_CR40","doi-asserted-by":"crossref","unstructured":"Shimada K, Suzuki R. Concurrent chemoradiotherapy for limited-stage extranodal natural killer\/T-cell lymphoma, nasal type. J Clin Oncol. 2010;28:e229 (author reply e230).","DOI":"10.1200\/JCO.2009.27.7574"},{"key":"1189_CR41","first-page":"116","volume":"2010","author":"SJ Kim","year":"2010","unstructured":"Kim SJ, Eom HS, Kim JS, Kwak JY, Yang DH, Park SK, et al. Concurrent chemo-radiotherapy followed by VIDL (etoposide, ifosfamide, dexamethasone, l-asparaginase) chemotherapy in stage I\/II extranodal NK\/T-cell lymphoma of nasal cavity\/nasopharynx. ASH Annu Meet Abstr. 2010;2010:116.","journal-title":"ASH Annu Meet Abstr"},{"key":"1189_CR42","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/annonc\/mdp412","volume":"21","author":"SJ Kim","year":"2010","unstructured":"Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, et al. When do we need central nervous system prophylaxis in patients with extranodal NK\/T-cell lymphoma, nasal type? Ann Oncol. 2010;21:1058\u201363.","journal-title":"Ann Oncol"},{"key":"1189_CR43","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/10428190600565651","volume":"47","author":"SJ Kim","year":"2006","unstructured":"Kim SJ, Kim BS, Choi CW, Seo HY, Seol HR, Sung HJ, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK\/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma. 2006;47:1265\u201373.","journal-title":"Leuk Lymphoma"},{"key":"1189_CR44","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2008.09.014","volume":"14","author":"J Lee","year":"2008","unstructured":"Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transpl. 2008;14:1356\u201364.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1189_CR45","unstructured":"Hyo R, Ishida F, Isobe K, Izutsu K, Kimura H, Kawa K, et al. Improved prognosis of NK-cell lymphoma\/leukemia, but not for T-cell lymphomas: a nationwide survey of NK- and associated T-cell neoplasms by the NK-Cell Tumor Study Group (NKTSG). Ann Oncol. 2011;22(suppl 4):iv164."},{"key":"1189_CR46","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.ijrobp.2010.10.040","volume":"82","author":"YX Li","year":"2012","unstructured":"Li YX, Wang H, Jin J, Wang WH, Liu QF, Song YW, et al. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK\/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2012;82:1809\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1189_CR47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijrobp.2007.05.073","volume":"70","author":"MJ Huang","year":"2008","unstructured":"Huang MJ, Jiang Y, Liu WP, Li ZP, Li M, Zhou L, et al. Early or up-front radiotherapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1189_CR48","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1002\/cncr.26167","volume":"117","author":"YX Li","year":"2011","unstructured":"Li YX, Liu QF, Wang WH, Jin J, Song YW, Wang SL, et al. Failure patterns and clinical implications in early stage nasal natural killer\/T-cell lymphoma treated with primary radiotherapy. Cancer. 2011;117:5203\u201311.","journal-title":"Cancer"},{"key":"1189_CR49","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1470-2045(09)70265-7","volume":"10","author":"YL Kwong","year":"2009","unstructured":"Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1093\u2013101.","journal-title":"Lancet Oncol."},{"key":"1189_CR50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1385\/MO:20:1:13","volume":"20","author":"A Aviles","year":"2003","unstructured":"Aviles A, Neri N, Fernandez R, Calva A, Huerta-Guzman J, Nambo MJ. Nasal NK\/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol. 2003;20:13\u20137.","journal-title":"Med Oncol"},{"key":"1189_CR51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02983387","volume":"78","author":"W Yong","year":"2003","unstructured":"Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal\/nasal-type T\/NK-cell lymphoma. Int J Hematol. 2003;78:163\u20137.","journal-title":"Int J Hematol"},{"key":"1189_CR52","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00277-008-0669-3","volume":"88","author":"W Yong","year":"2009","unstructured":"Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, et al. l-Asparaginase in the treatment of refractory and relapsed extranodal NK\/T-cell lymphoma, nasal type. Ann Hematol. 2009;88:647\u201352.","journal-title":"Ann Hematol"},{"key":"1189_CR53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/annonc\/mdn551","volume":"20","author":"BS Kim","year":"2009","unstructured":"Kim BS, Kim DW, Im SA, Kim CW, Kim TY, Yoon SS, et al. Effective second-line chemotherapy for extranodal NK\/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol. 2009;20:121\u20138.","journal-title":"Ann Oncol"},{"key":"1189_CR54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.23144","volume":"87","author":"JO Armitage","year":"2012","unstructured":"Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87:511\u20139.","journal-title":"Am J Hematol"},{"key":"1189_CR55","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1600-0609.2009.01395.x","volume":"84","author":"Y Tsukune","year":"2010","unstructured":"Tsukune Y, Isobe Y, Yasuda H, Shimizu S, Katsuoka Y, Hosone M, et al. Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. Eur J Haematol. 2010;84:310\u20135.","journal-title":"Eur J Haematol"},{"key":"1189_CR56","first-page":"2688","volume":"118","author":"MA Lunning","year":"2011","unstructured":"Lunning MA, Pamer E, Wintman L, Bhatt V, Yahalom J, Moskowitz AJ, et al. Modified SMILE in the treatment of natural killer T-cell lymphoma, nasal and nasal type: a single center US experience. ASH Annu Meet Abstr. 2011;118:2688.","journal-title":"ASH Annu Meet Abstr."},{"key":"1189_CR57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/annonc\/mdn542","volume":"20","author":"A Jaccard","year":"2009","unstructured":"Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, et al. l-Asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009;20:110\u20136.","journal-title":"Ann Oncol"},{"key":"1189_CR58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","volume":"130","author":"N Murashige","year":"2005","unstructured":"Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561\u20137.","journal-title":"Br J Haematol"},{"key":"1189_CR59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705244","volume":"37","author":"R Suzuki","year":"2006","unstructured":"Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka JI, Sakai C, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transpl. 2006;37:425\u201331.","journal-title":"Bone Marrow Transpl"},{"key":"1189_CR60","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3109\/10428194.2010.487958","volume":"51","author":"H Yokoyama","year":"2010","unstructured":"Yokoyama H, Yamamoto J, Tohmiya Y, Yamada MF, Ohguchi H, Ohnishi Y, et al. Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer\/T cell lymphoma, nasal type. Leuk Lymphoma. 2010;51:1509\u201312.","journal-title":"Leuk Lymphoma"},{"key":"1189_CR61","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s12032-010-9532-1","volume":"28","author":"M Li","year":"2011","unstructured":"Li M, Gao C, Li H, Wang Z, Cao Y, Huang W, et al. Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK\/T-cell lymphoma. Med Oncol. 2011;28:840\u20135.","journal-title":"Med Oncol"},{"key":"1189_CR62","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s12185-010-0726-2","volume":"92","author":"R Suzuki","year":"2010","unstructured":"Suzuki R. Treatment of advanced extranodal NK\/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol. 2010;92:697\u2013701.","journal-title":"Int J Hematol"},{"key":"1189_CR63","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1182\/blood-2011-05-354142","volume":"118","author":"R Suzuki","year":"2011","unstructured":"Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, et al. Prospective measurement of Epstein\u2013Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2011;118:6018\u201322.","journal-title":"Blood"},{"key":"1189_CR64","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1158\/1078-0432.CCR-12-1064","volume":"18","author":"Y Ito","year":"2012","unstructured":"Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK\/T-cell lymphoma, nasal type. Clin Cancer Res. 2012;18:4183\u201390.","journal-title":"Clin Cancer Res."},{"key":"1189_CR65","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"N Tsukamoto","year":"2007","unstructured":"Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652\u20139.","journal-title":"Cancer"},{"key":"1189_CR66","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdm265","volume":"18","author":"S Kako","year":"2007","unstructured":"Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685\u201390.","journal-title":"Ann Oncol"},{"key":"1189_CR67","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3816\/CLM.2008.n.010","volume":"8","author":"D Karantanis","year":"2008","unstructured":"Karantanis D, Subramaniam RM, Peller PJ, Lowe VJ, Durski JM, Collins DA, et al. The value of [(18)F]fluorodeoxyglucose positron emission tomography\/computed tomography in extranodal natural killer\/T-cell lymphoma. Clin Lymphoma Myeloma. 2008;8:94\u20139.","journal-title":"Clin Lymphoma Myeloma."},{"key":"1189_CR68","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00277-008-0494-8","volume":"87","author":"PL Khong","year":"2008","unstructured":"Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613\u201321.","journal-title":"Ann Hematol"},{"key":"1189_CR69","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2967\/jnumed.108.053355","volume":"49","author":"C Suh","year":"2008","unstructured":"Suh C, Kang YK, Roh JL, Kim MR, Kim JS, Huh J, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer\/T-cell lymphomas of the head and neck. J Nucl Med. 2008;49:1783\u20139.","journal-title":"J Nucl Med"},{"key":"1189_CR70","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/annonc\/mdq415","volume":"22","author":"X Cahu","year":"2011","unstructured":"Cahu X, Bodet-Milin C, Brissot E, Maisonneuve H, Houot R, Morineau N, et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T\/NK lymphomas: a study from the GOELAMS group. Ann Oncol. 2011;22:705\u201311.","journal-title":"Ann Oncol"},{"key":"1189_CR71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0609.2011.01645.x","volume":"87","author":"H Fujiwara","year":"2011","unstructured":"Fujiwara H, Maeda Y, Nawa Y, Yamakura M, Ennishi D, Miyazaki Y, et al. The utility of positron emission tomography\/computed tomography in the staging of extranodal natural killer\/T-cell lymphoma. Eur J Haematol. 2011;87:123\u20139.","journal-title":"Eur J Haematol"},{"key":"1189_CR72","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1158\/1078-0432.CCR-06-2373","volume":"13","author":"J Lee","year":"2007","unstructured":"Lee J, Suh C, Huh J, Jun HJ, Kim K, Jung C, et al. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer\/T-cell lymphoma, nasal-type. Clin Cancer Res. 2007;13:3250\u20134.","journal-title":"Clin Cancer Res"},{"key":"1189_CR73","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/PAS.0b013e31824433d8","volume":"36","author":"T Pongpruttipan","year":"2012","unstructured":"Pongpruttipan T, Sukpanichnant S, Assanasen T, Wannakrairot P, Boonsakan P, Kanoksil W, et al. Extranodal NK\/T-cell lymphoma, nasal type, includes cases of natural killer cell and alphabeta, gammadelta, and alphabeta\/gammadelta T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36:481\u201399.","journal-title":"Am J Surg Pathol"},{"key":"1189_CR74","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812\u201321.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1189-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1189-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1189-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T22:24:01Z","timestamp":1594765441000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1189-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,17]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1189-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,17]]}}}